Molecular characterization of Iranian patients with type 3 von Willebrand disease

Haemophilia

Volumn 15, Issue 5, 2009, Pages 1058-1064

  Shahbazi, S ^a   Mahdian, R ^b   Ala, F A ^c   Lavergne, J M ^a   Denis, C V ^a   Christophe, Olivier D ^a,d  

^a UNIVERSITÉ PARIS SACLAY   (France)

^b PASTEUR INSTITUTE OF IRAN   (Iran)

^c Iranian Comprehensive Haemophilia Care Centre   (Iran)

^d BICÊTRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

VON WILLEBRAND FACTOR;

ADULT; ARTICLE; BLEEDING; CLINICAL ARTICLE; CONSANGUINITY; CONTROLLED STUDY; DISEASE SEVERITY; DNA FLANKING REGION; EPISTAXIS; EXON; FEMALE; GENE AMPLIFICATION; GENE DELETION; GENE MUTATION; GENE SEQUENCE; GENETIC ANALYSIS; GENETIC HETEROGENEITY; HEMARTHROSIS; HOMOZYGOSITY; HUMAN; IRAN; MALE; MENORRHAGIA; MUSCLE HEMATOMA; NONSENSE MUTATION; NULL ALLELE; POLYMERASE CHAIN REACTION; POSTOPERATIVE HEMORRHAGE; POSTPARTUM HEMORRHAGE; PRIORITY JOURNAL; RNA SPLICING; SYMPTOMATOLOGY; TOOTH EXTRACTION; VON WILLEBRAND DISEASE; VON WILLEBRAND DISEASE TYPE 3;

ADULT; CODON, NONSENSE; EXONS; FEMALE; GENES, RECESSIVE; GENETIC HETEROGENEITY; GENETIC TESTING; GENOTYPE; HUMANS; IRAN; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; PEDIGREE; PHENOTYPE; POLYMERASE CHAIN REACTION; PREVALENCE; SEQUENCE ANALYSIS, DNA; SEVERITY OF ILLNESS INDEX; VON WILLEBRAND DISEASE, TYPE 3; YOUNG ADULT;

EID: 69949099126     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2009.02046.x     Document Type: Article

References (31)

1. Denis CV. Molecular and cellular biology of von Willebrand factor. Int J Hematol 2002; 75: 3-8.
2. Mancuso DJ, Tuley EA, Westfield LA et al. Human von Willebrand factor gene and pseudogene: Structural analysis and differentiation by polymerase chain reaction. Biochemistry 1991; 30: 253-69.
3. Mancuso DJ, Tuley EA, Westfield LA et al. Structure of the gene for human von Willebrand factor. J Biol Chem 1989; 264: 19514-27.
4. Sadler JE, Budde U, Eikenboom JC et al. Update on the pathophysiology and classification of von Willebrand disease: A report of the Subcommittee on von Willebrand Factor. J Thromb Haemost 2006; 4: 2103-14.
5. Mannucci PM, Bloom AL, Larrieu MJ, Nilsson IM, West RR. Atherosclerosis and von Willebrand factor. I. Prevalence of severe von Willebrand's disease in western Europe and Israel. Br J Haematol 1984; 57: 163-9.
6. Berliner SA, Seligsohn U, Zivelin A, Zwang E, Sofferman G. A relatively high frequency of severe (type III) von Willebrand's disease in Israel. Br J Haematol 1986; 62: 535-43.
7. Lak M, Peyvandi F, Mannucci PM. Clinical manifestations and complications of childbirth and replacement therapy in 385 Iranian patients with type 3 von Willebrand disease. Br J Haematol 2000; 111: 1236-9.
8. ISTH SSC VWF Database. http://www.vwf.group.shef.ac.uk (last accessed on 1 March 2009).
9. Tosetto A, Rodeghiero F, Castaman G et al. A quantitative analysis of bleeding symptoms in type 1 von Willebrand disease: Results from a multicenter European study (MCMDM-1 VWD). J Thromb Haemost 2006; 4: 766-73.
10. Goodeve AC, Eikenboom JC, Ginsburg D et al. A standard nomenclature for von Willebrand factor gene mutations and polymorphisms. On behalf of the ISTH SSC Subcommittee on von Willebrand factor. Thromb Haemost 2001; 85: 929-31.
11. Baronciani L, Cozzi G, Canciani MT et al. Molecular defects in type 3 von Willebrand disease: Updated results from 40 multiethnic patients. Blood Cells Mol Dis 2003; 30: 264-70.
12. Sadler JE, Mannucci PM, Berntorp E et al. Impact, diagnosis and treatment of von Willebrand disease. Thromb Haemost 2000; 84: 160-74.
13. Rodeghiero F, Castaman G, Tosetto A et al. The discriminant power of bleeding history for the diagnosis of type 1 von Willebrand disease: An international, multicenter study. J Thromb Haemost 2005; 3: 2619-26.
14. Castaman G, Rodeghiero F, Tosetto A et al. Hemorrhagic symptoms and bleeding risk in obligatory carriers of type 3 von Willebrand disease: an international, multicenter study. J Thromb Haemost 2006; 4: 2164-9.
15. Tosetto A, Castaman G, Rodeghiero F. Evidence-based diagnosis of type 1 von Willebrand disease: A Bayes theorem approach. Blood 2008; 111: 3998-4003.
16. Goodeve A, Eikenboom J, Castaman G et al. Phenotype and genotype of a cohort of families historically diagnosed with type 1 von Willebrand disease in the European study, molecular and clinical markers for the diagnosis and management of type 1 von Willebrand disease (MCMDM-1VWD). Blood 2007; 109: 112-21.
17. Baronciani L, Cozzi G, Canciani MT et al. Molecular characterization of a multiethnic group of 21 patients with type 3 von Willebrand disease. Thromb Haemost 2000; 84: 536-40.
18. Gupta PK, Saxena R, Adamtziki E et al. Genetic defects in von Willebrand disease type 3 in Indian and Greek patients. Blood Cells Mol Dis 2008; 41: 219-22.
19. Ng PC, Henikoff S. Predicting the effects of amino acid substitutions on protein function. Annu Rev Genomics Hum Genet 2006; 7: 61-80.
20. Cooper DN, Krawczak M. The mutational spectrum of single base-pair substitutions causing human genetic disease: Patterns and predictions. Hum Genet 1990; 85: 55-74.
21. Shelton-Inloes BB, Chehab FF, Mannucci PM, Federici AB, Sadler JE. Gene deletions correlate with the development of alloantibodies in von Willebrand disease. J Clin Invest 1987; 79: 1459-65.
22. Ngo KY, Glotz VT, Koziol JA et al. Homozygous and heterozygous deletions of the von Willebrand factor gene in patients and carriers of severe von Willebrand disease. Proc Natl Acad Sci USA 1988; 85: 2753-7.
23. Mancuso DJ, Tuley EA, Castillo R, de Bosch N, Mannucci PM, Sadler JE. Characterization of partial gene deletions in type III von Willebrand disease with alloantibody inhibitors. Thromb Haemost 1994; 72: 180-5.
24. Peake IR, Liddell MB, Moodie P et al. Severe type III von Willebrand's disease caused by deletion of exon 42 of the von Willebrand factor gene: family studies that identify carriers of the condition and a compound heterozygous individual. Blood 1990; 75: 654-61.
25. Zhang ZP, Lindstedt M, Falk G, Blomback M, Egberg N, Anvret M. Nonsense mutations of the von Willebrand factor gene in patients with von Willebrand disease type III and type I. Am J Hum Genet 1992; 51: 850-8.
26. Surdhar GK, Enayat MS, Lawson S, Williams MD, Hill FG. Homozygous gene conversion in von Willebrand factor gene as a cause of type 3 von Willebrand disease and predisposition to inhibitor development. Blood 2001; 98: 248-50.
27. Hentze MW, Kulozik AE. A perfect message: RNA surveillance and nonsense-mediated decay. Cell 1999; 96: 307-10.
28. Krawczak M, Cooper DN. Gene deletions causing human genetic disease: mechanisms of mutagenesis and the role of the local DNA sequence environment. Hum Genet 1991; 86: 425-41.
29. Houdayer C, Dehainault C, Mattler C et al. Evaluation of in silico splice tools for decision-making in molecular diagnosis. Hum Mutat 2008; 29: 975-82.
30. Reese MG, Eeckman FH, Kulp D, Haussler D. Improved splice site detection in Genie. J Comput Biol 1997; 4: 311-23.
31. Brunak S, Engelbrecht J, Knudsen S. Prediction of human mRNA donor and acceptor sites from the DNA sequence. J Mol Biol 1991; 220: 49-65.